King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Aisha Alshibani
Dr. Aisha Alshibani is a Consultant in General Medical Oncology with clinical and research expertise in solid tumours, soft tissue sarcomas, and breast cancer — a dedicated Medical Oncologist in Riyadh, Saudi Arabia providing evidence-based systemic therapy for international patients seeking advanced cancer care in the Middle East. Her published work spans sarcoma minimal residual disease (MRD) detection, pazopanib therapy, and meningioma management.
- Consultant Medical Oncologist specialising in solid tumours, sarcomas, and breast cancer
- Co-author on international sarcoma and MRD research presented at major oncology meetings
- Published contributor to leading international oncology and sarcoma journals
- Active researcher in targeted therapy, immunotherapy, and molecular profiling for solid tumours
- Experienced in treating international patients from the Gulf, Africa, and South Asia
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency
- Subspecialty Training in Medical Oncology
Fellowships & Special Training
- Fellowship in Medical Oncology — King Faisal Specialist Hospital & Research Centre, Riyadh
- Advanced training in Solid Tumours and Sarcoma Management
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- American Society of Clinical Oncology (ASCO) — Member
Areas of Expertise
Major Conditions Treated
- Breast Cancer
- Soft Tissue Sarcomas (STS)
- Bone Sarcomas
- Gastrointestinal Cancers
- Lung Cancer
- Meningioma (Systemic Therapy)
- Gynaecological Malignancies
- Genitourinary Cancers
Sub-specialties
- Sarcoma Medical Oncology: Evidence-based systemic therapy for soft tissue and bone sarcomas including pazopanib, trabectedin, and selinexor-based regimens — a leading sarcoma specialist in Riyadh for international patients seeking complex solid tumour care.
- Breast Cancer Systemic Therapy: Precision oncology using Oncotype DX molecular profiling, HER2-targeted therapy, and endocrine therapy for early and metastatic breast cancer.
- Minimal Residual Disease (MRD) Research: Active investigator in circulating tumour DNA and MRD-guided treatment strategies in soft tissue sarcoma and other solid tumours.
Advanced Procedures & Treatments
- Chemotherapy (IV and Oral Regimens)
- Targeted Therapy (Pazopanib, Trabectedin, Selinexor)
- Immunotherapy / Checkpoint Inhibitors (PD-1, PD-L1)
- HER2-Targeted Therapy (Trastuzumab, Pertuzumab, T-DXd)
- Hormone Therapy (Breast Cancer)
- Circulating Tumour DNA & MRD Monitoring
- Molecular Tumour Profiling (Oncotype DX, NGS)
- Clinical Trial Enrolment
Professional Experience
Current Affiliation
- Consultant, General Medical Oncology — King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia (Present)
Past Affiliations
- Fellow, Medical Oncology — King Faisal Specialist Hospital & Research Centre, Riyadh (Fellowship period)
Academic & Research Roles
- Participant — KFSHRC Multidisciplinary Tumour Board (Sarcoma and Solid Tumours)
- Contributor — ASCO Annual Meeting (2023, 2024) scientific sessions
Key Achievements
- Co-author on abstract (11537) on MRD detection in soft tissue sarcoma
- Contributor to selinexor-based sarcoma combination therapy research
- Published contributor to leading international sarcoma and oncology journals
- Active member of KFSHRC sarcoma programme — one of the largest sarcoma referral centres in the region
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- Saudi Oncology Society
- Saudi Commission for Health Specialties (SCFHS)
Research & Publications
Published Papers (Selected)
- Shoag JM, et al. Atypical Meningioma Case Report. Cureus. 2020. PMC8288198.
- Alshamsan B, Alshibany A, et al. Neutrophil-to-Lymphocyte Ratio and Oncotype DX in Breast Cancer. 2021. PMC8721024.
- Badran A, Alshibany A, et al. Efficacy of Pazopanib in Soft Tissue Sarcoma. Clinical Sarcoma Research. 2021. PMC8414075.
- Alshibany A, et al. Selinexor Combination Therapy in Advanced Soft Tissue Sarcoma (ASCO 2023 abstract).
- Alshibany A, et al. Minimal Residual Disease Detection in Soft Tissue Sarcoma (ASCO 2024 abstract 11537).
Ongoing Research & Clinical Interests
- Minimal residual disease and circulating tumour DNA in solid tumours
- Targeted therapy in soft tissue sarcoma
- Molecular profiling in breast cancer
- Immunotherapy in rare solid tumours
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Medical Oncology Consultation | ₹1,000 – ₹2,500 | $12 – $30 |
| Chemotherapy (per cycle, regimen-dependent) | ₹20,000 – ₹1,50,000 | $240 – $1,800 |
| Targeted Therapy (per month, drug-dependent) | ₹50,000 – ₹3,00,000 | $600 – $3,600 |
| Immunotherapy (per cycle) | ₹80,000 – ₹2,50,000 | $960 – $3,000 |
| Tumour Marker Panel / Molecular Profiling | ₹5,000 – ₹50,000 | $60 – $600 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Aisha Alshibani use in Medical Oncology treatment?
Dr. Aisha Alshibani uses advanced evidence-based medical oncology tools including next-generation sequencing (NGS), circulating tumour DNA (ctDNA) monitoring, Oncotype DX molecular profiling, targeted therapy regimens (pazopanib, trabectedin, selinexor), and immunotherapy protocols (PD-1/PD-L1 checkpoint inhibitors). Virtual consultations and remote second opinions are also available to international patients through Cancer Rounds.
2. What conditions does Dr. Aisha Alshibani specialize in treating?
Dr. Aisha Alshibani specialises in Medical Oncology, treating soft tissue sarcomas, bone sarcomas, breast cancer, gastrointestinal and lung cancers, gynaecological malignancies, and meningiomas requiring systemic therapy. International patients seeking the best medical oncologist in India or Saudi Arabia for second opinions and advanced systemic therapy benefit from her expertise in MRD-guided treatment and precision oncology.
3. How do I book an appointment with Dr. Aisha Alshibani?
Appointments with Dr. Aisha Alshibani can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Aisha Alshibani?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Aisha Alshibani, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Aisha Alshibani offer second opinions for Medical Oncology cases?
Yes. Second opinion consultations for Medical Oncology cases can be arranged via Cancer Rounds, connecting international patients with Dr. Aisha Alshibani to review diagnoses, pathology reports, and treatment plans — particularly valuable for complex sarcoma and advanced breast cancer cases.
